Found 28 Non-Small Cell Lung Cancer trials
A listing of Non-Small Cell Lung Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
The primary outcomes will be to establish the safety and feasibility of inhaled imaging in patients with NSCLCand to develop a robust RT planning protocol incorporating both standard of care metrics and those derived from inhaled imaging
Request for collaborative review: WIRB serving as IRB of record.
This study will consider the safety and effectiveness of a study drug, CAN04, in combination with pembrolizumab, in the treatment of incurable or metastatic non-small-cell lung cancer, head and neck squamous cell carcinoma, urothelial cancer, or malignant melanoma. The study aims to establish a recommended dose of CAN04 in combination …
The purpose of this study is to find if adding the study drug, nivolumab (also known as OPVIDO), will limit lung cancer from growing back in patients with early stage non-small cell lung cancer. Nivolumab is a drug that may turn on the body's immune system to attack any cancer …
This is a phase 1 study with Highly-selective RET inhibiter, Blu-667, in patients with Thyroid Cancer, Non-Small cell lung cancer and other advanced solid tumors. The study will be conducted at multiple centers in the United States and Europe. the purpose of this trial is to determine the maximum tolerated …
The purpose of this study is to determine if the combination of the three anti-cancer drugs carboplatin, paclitaxel, and ramucirumab is helpful in shrinking tumors or delaying tumor growth in participants with non-small cell lung cancer. This study will also assess whether it is safe to combine these drugs.Participants for …
This trial is to evaluate the safety and efficacy of adding GMCI to standard of care in patients with stage III/IV NSCLC that are not responding to a first line immune checkpoint inhibitor (ICI).
LOXO-292 is a highly potent and specific inhibitor of the RET RTK, with minimal inhibition of other kinase and non-kinase targets, and therefore may be of benefit to patients with tumors (such as NSCLC, MTC, PTC, and colon or breast carcinomas) that harbor RET alterations and/or depend on RET activation. …
